- Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics Announces Changes to Board of Directors
- Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
- Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
- Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
More ▼
Key statistics
As of last trade Black Diamond Therapeutics Inc (BDTX:NSQ) traded at 4.88, -36.29% below its 52-week high of 7.66, set on May 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.03 |
---|---|
High | 5.04 |
Low | 4.80 |
Bid | 4.88 |
Offer | 4.90 |
Previous close | 5.04 |
Average volume | 1.05m |
---|---|
Shares outstanding | 56.25m |
Free float | 54.94m |
P/E (TTM) | -- |
Market cap | 283.51m USD |
EPS (TTM) | -1.70 USD |
Data delayed at least 15 minutes, as of May 23 2024 14:46 BST.
More ▼